^(153)钐-乙二胺四甲撑膦酸治疗癌症转移患者骨痛疗效分析  

Comparative analyses of samarium153ethylenediamine tetramethyline phosphonic acid therapy on osseous metastases in aged

作　　者：杨一峰[1] 钱忠豪[1] 顾宇参[1] 许峥[1] 蒋长英[1] 

机构地区：[1]上海医科大学附属中山医院

出　　处：《中华老年医学杂志》1998年第2期100-102,共3页Chinese Journal of Geriatrics

摘　　要：目的探讨老年癌症骨转移患者内照射治疗的剂量效应。方法对用１５３钐－乙二胺四甲撑膦酸（１５３Ｓｍ－ＥＤＴＭＰ）治疗而缓解癌性骨痛的老年患者４０例作骨辐射吸收剂量分析和疗效观察，并以老年前期组４０例癌性骨痛治疗者为对照。结果老年组及老年前期两组在尿排泄率、骨摄取率及骨累积活度的差异无显著性；其疗效分别为４５％及６０％，老年组稍低于老年前期组，但差异无显著性（均为Ｐ＞０．０５）；红骨髓辐射吸收剂量相似，分别为２１９．９±６８．２及２０６．３±６４．７ｃＧｙ，均在安全剂量范围（２８５ｃＧｙ）内。结论增龄不影响老年人１５３Ｓｍ－ＥＤＴＭＰ治疗缓解癌性骨痛的剂量效应。Objective To study the doseresponse of internal radiation therapy in aged patients with osseous metastases. Methods Samarium153ethylenediamine tetramethyline phosphonic acid(153 SmEDTMP) was administrated to a group of 40 patients aged ≥60y and another group aged from 45y to 59y as control for palliating painful bone metastases. Comparative analyses were made on the doseresponse rate and absorbed dose of bone radiation between the two groups. Results Differences of urine excretion rate, skeletal uptake rate and accumulated skeletal activities between the two groups were of no significance (P>005). The response rate was 45% (age≥60y) and 60% (age from 45y to 59y) respectively. Although the elder group was lower in response the difference was of no significance (P>005). The average radiation absorbed dose by red marrow was similar in the two groups. Both were within the safe dose range. Conclusions Aging has no influence on doseresponse in 153 SmEDTMP therapy to painful bone metastases patients.

关 键 词：剂量 钐153 乙二胺四甲撑 膦酸 骨转移瘤 疼痛 

分 类 号：R738.105[医药卫生—肿瘤] R441.1[医药卫生—临床医学]